Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Vonoprazan

(Voquezna®)

Voquezna®

Drug updated on 4/18/2024

Dosage FormTablet (oral; 10 mg, 20 mg)
Drug ClassPotassium-competitive acid blockers
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.
  • Indicated for maintaining healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.
  • Indicated in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults.
  • Indicated in combination with amoxicillin for the treatment of H. pylori infection in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vonoprazan and amoxicillin (Dual Pak) and vonoprazan, amoxicillin, and clarithromycin (Triple Pak: Voquezna) are used for healing all grades of erosive esophagitis, providing relief from heartburn associated with erosive esophagitis, maintaining the healing of all grades of erosive esophagitis, and providing relief from heartburn. They are also recommended for treating Helicobacter pylori infection in combination with amoxicillin or both amoxicillin and clarithromycin.
  • Thirty-five studies were analyzed to collect data on Voquezna.
  • Compared to traditional triple therapies that include proton pump inhibitors (PPIs) or bismuth quadruple therapy, Voquezna shows superior eradication rates against H. pylori infection by achieving significantly higher intention-to-treat and per-protocol eradication rates.
  • Voquezna offers a favorable profile for managing post-endoscopic submucosal dissection ulcers by reducing the rates of delayed postoperative bleeding compared to PPIs, indicating its potential use in scenarios where rapid ulcer healing is crucial.
  • Voquezna is associated with lower adverse events than traditional therapies across various scenarios, such as treatment for H. pylori infections or managing post-endoscopic submucosal dissection ulcers, indicating better tolerance among individuals.
  • In cases of refractory gastroesophageal reflux disease resistant to proton pump inhibitor therapy, vonoprazan-based therapy demonstrates promising results, improving outcomes where PPI therapy is inadequate.
  • For strains of H. pylori resistant to clarithromycin, Voquezna-based therapy shows superiority, highlighting its important role in combating antibiotic resistance.
  • Some studies have noted varying efficacy rates between different regions, suggesting that regional bacterial resistance patterns, dietary habits, or genetic factors might influence treatment outcomes, emphasizing the importance of considering local success rates when choosing an eradication regimen.

Product Monograph / Prescribing Information

Document TitleYearSource
Voquezna (vonoprazan) prescribing information.2023Phathom Pharmaceuticals Inc., Buffalo Grove, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of vonoprazan and proton pump inhibitors for the treatment of gastric endoscopic submucosal dissection-induced ulcer: an updated systematic review and meta-analysis.2024BMC Gastroenterology
Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.2024Helicobacter
Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: a systematic review with meta-analysis of randomized controlled trials.2024Journal of Gastroenterology and Hepatology
Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.2024Pharmacotherapy
A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.2024Journal of Gastroenterology and Hepatology
The efficacy and safety of regimens for helicobacter pylori eradication treatment in china: a systemic review and network meta-analysis.2024Journal of Clinical Gastroenterology
Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis.2024Helicobacter
Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis.2024Helicobacter
The efficacy and safety of vonoprazan and amoxicillin dual therapy for helicobacter pylori infection: a systematic review and network meta-analysis.2023Antibiotics
Efficacy and safety of vonoprazan and amoxicillin dual therapy for helicobacter pylori eradication: a systematic review and meta-analysis. 2023Digestion
Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. 2023Saudi Journal of Gastroenterology
The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis. 2023European Journal of medical research
Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis.2023Frontiers in Pharmacology
Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.2023Journal of Comparative Effectiveness Research
Vonoprazan versus lansoprazole in erosive esophagitis - a systematic review and meta-analysis of randomized controlled trials.2023Indian Journal of Gastroenterology
Incidence and type of adverse events in patients taking vonoprazan: a systematic review and meta-analysis.2023Therapeutic Advances in Gastroenterology
Third-line and rescue therapy for refractory Helicobacter pylori infection: a systematic review2023World Journal of Gastroenterology
Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.2023European Journal of Clinical Pharmacology
Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials.2023Gut
Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis.2022Therapeutic Advances in Gastroenterology
A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis.2022Journal of Gastroenterology and Hepatology
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: a PRISMA-compliant systematic review and network meta-analysis.2022Medicine
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials.2022Journal of Clinical Pharmacy and Therapeutics
Network meta-analysis comparing vonoprazan and proton pump inhibitors for heartburn symptoms in erosive esophagitis.2022Journal of Clinical Gastroenterology
Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis.2022Journal of Gastroenterology and Hepatology
Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line helicobacter pylori eradication therapy: systematic review and meta-analysis.2021Digestion
Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis.2021Digestive Diseases and Sciences
Comparative effectiveness of multiple different first-line treatment regimens for helicobacter pylori infection: a network meta-analysis.2021Gastroenterology
Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: a meta-analysis of randomized controlled trials and observational studies.2020Medicine
The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis.2019Journal of Digestive Diseases
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.2019Journal of Gastroenterology
Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis.2019Medicine
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review.2019Journal of Gastroenterology and Hepatology
Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for helicobacter pylori eradication: a meta-analysis of randomized clinical trials.2019BioMed Research International
Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis.2019Surgical Endoscopy
Comparison of the use of vonoprazan and proton pump inhibitors for the treatment of peptic ulcers resulting from endoscopic submucosal dissection: a systematic review and meta-analysis.2019Medical Science Monitor

Clinical Practice Guidelines

Document TitleYearSource
Reconciliation of recent helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics.2019Gastroenterology